©2025 Stanford Medicine
Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)
Not Recruiting
Trial ID: NCT02220309
Purpose
This research study is aimed at understanding behaviors and brain circuits that relate to anxiety and depression. Our goal is to learn which circuits of the brain are involved in anxiety and how these circuits might affect daily functioning.
This study has recently added an additional treatment component: participants undergo a 12 week course of either Pramipexole medication or rTMS therapy (explained below). The ultimate goal of the study is to offer participants experiencing anxiety and depression a treatment that is alternative to ones that have failed them in the past, and to apply the knowledge we gain from investigating the brain circuits involved in anxiety and depression to help personalize treatments.
We invite anyone who has recently experienced any symptoms of anxiety and/or depression to participate (no diagnosis is required to participate).
Official Title
Neural Dimensions of Threat Reactivity and Regulation for Understanding Anxiety
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
* Recent experiences of anxiety and/or depression
* Ages 18-65
Exclusion Criteria:
* Specific psychiatric medications (case-by-case basis)
* A diagnosis of Bipolar 1 Disorder, Schizophrenia, or Obsessive Compulsive Disorder
* Any of the following medical conditions: Parkinson's disease; liver or kidney disease; history of epilepsy or seizures; history of cardiovascular disorders (specifically orthostatic hypotension)
Intervention(s):
drug: Pramipexole Oral Tablet
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Nowreen Chowdhry, B.S.
(650) 497-6480